Eaton Vance中期市政收入主动型ETF EVIM 深 沪
等待开盘 08-20 09:30:00 美东时间
52.53
+0.120
+0.23%
华盛通- 最 高52.56
- 今 开52.50
- 成交量 6.33万股
- 最 低 52.48
- 昨 收 52.41
- 总市值 2.84亿
- 52周最高 53.2897
- 市盈率 静 --
- 换手率 1.17%
- 52周最低 49.604
- 委 比 -77.78%
- 总股本 540.00万
- 历史最高 53.2897
- 量 比 2.95
- 振 幅 0.15%
- 历史最低 44.551
- 每 手 1
- 风险率 0.83%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Pusula Finans Holding Nudges Up Stake in Katılımevim Tasarruf Finansman
KATILIMEVIM TASARRUF FINANSMAN A.S. ( ($TR:KTLEV) ) has shared an update. Pusul...
08-10 19:45
Katilimevim Secures Regulator Approval for Bonus Capital Increase
KATILIMEVIM TASARRUF FINANSMAN A.S. ( ($TR:KTLEV) ) has provided an announcemen...
08-04 00:04
Katılımevim Reports TRY 41.2 Billion Contract Volume for July 2026
An update from KATILIMEVIM TASARRUF FINANSMAN A.S. ( ($TR:KTLEV) ) is now avail...
08-03 16:16
BeOne Medicines Publishes Data From HERIZON-GEA-01 In The New England Journal Of Medicine, To Present Oral Presentation At American Society Of Clinical Oncology On June 1
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that data from HERIZON-GEA-01 were published in The New England Journal of Medicine and will be presented in an
05-28 05:03
FDA Grants Priority Review To BeOne Medicines' Supplemental Biologics License Application For Tevimbra (Tislelizumab) In Combination With Ziihera (Zanidatamab) And Chemotherapy For Untreated Unresectable Locally Advanced/Metastatic HER2-positive Gastric, Gastroesophageal Junction, Or Esophageal Adenocarcinoma
TEVIMBRA plus ZIIHERA and chemotherapy regimen delivered statistically significant median OS of 26.4 months, an unprecedented result in this challenging diseaseResults from the global Phase 3 HERIZON-GEA-01 study
04-29 18:03
